Cellares is partnering with Taiwanese biotech GenomeFrontier Therapeutics to evaluate the integrated contract developer and manufacturer’s cell shuttle platform for use in the production of virus-free CAR-T therapies.
Trialynx takes home the DPHARM Idol Disrupt award from the 2026 DPHARM conference.
Major companies including PepsiCo, Cigna and Starbucks reportedly limiting GLP-1 coverage
There is reason to be cautiously optimistic about the trajectory of the current Ebola outbreak in the Democratic Republic of the Congo, the WHO says.
STAT•Helen Branswell2h ago
The DRC faces a growing Ebola threat as cases soar in North Kivu, despite progress in other regions, says Tedros
Al Jazeera2h ago
In patients with newly diagnosed stage IVB cervical cancer, adding definitive-dose pelvic radiotherapy to chemotherapy was associated with longer survival compared with chemotherapy alone. Medscape Medical News
Medscape2h ago
As Amgen advances its bid to join the first wave of biosimilars to Bristol Myer Squibb and Ono’s oncology megablockbuster Opdivo, the originator drug’s partners are not taking the challenge lying down.
The World Health Organization said Wednesday that the fight against the Ebola outbreak in DR Congo was showing “encouraging signs" but that the epidemic was "far from over". More than 7,000 cases have been reported across seven provinces as of September 11.
The deal underscores a broader push by drugmakers to integrate AI across research and development to boost new drug discovery.
Euronews3h ago
Novartis has extended its losing streak, stopping an amyotrophic lateral sclerosis program after flunking a phase 2 trial.
Legend Biotech has found its permanent CEO, poaching 15-year Novartis veteran Ingrid Zhang as the CAR-T specialist eyes its next phase of growth.
The health and hygiene conglomerate, known for brands like Lysol and Mucinex, will spend the funds building out an R&D hub at its new headquarters and finalizing the largest of its seven manufacturing sites by 50%.
